ExpreS2ion Biotech

Opdaterede Investeringscases på ExpreS2ion og TORM, overtegnet emission i Rovsing og Q1-regnskab fra Curasight.

In connection with the Q1 2026 report, we have updated our investment case. Q1 2026 has moved ExpreS2ion meaningfully forward and further derisked the investment case, with continued positive ES2B-C001 read-outs, a redesigned and strengthened Phase I programme, and a completed rights issue potentially securing the company's path to the end-2026 Phase I read-out.

Today, ExpreS2ion Biotechnologies' management presented the financial results for Q1 2026, provided further insights into the recent pipeline developments with focus on the breast cancer, malaria and Nipah candidates, and shared the latest updates on the completed rights issue and the partnering outlook for ES2B-C001.

ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.

Markederne lukkede i går aftes i nye rekordniveauer, men her til morgen peger futures ned efter nye angreb på Iran. Herhjemme fokus på børsnoteringen af Biomar og Q1 fra Per Aarsleff, Imperio og ExpreS2ion.

Dagens aktienyheder 28/05-2026: Biomar, Impero og ExpreS2ion

Her til formiddag kl. 10:00 vil ExpreS2ion Biotech CEO Bent U. Frandsen og CFO Keith Alexander præsentere Q1 2026 delårsrapporten og svare på spørgsmål fra publikum. Tilmeld dig og stil dine spørgsmål allerede nu.

Dagens aktienyheder 20/05-2026: Biomar, ISS A/S, ExpreS2ion, WindowMaster, Scandinavian Medical Solutions og Trifork

ExpreS2ion today announced an update to the Phase I program for ES2B-C001 alongside additional preliminary observations and study design changes. Anti-HER2 antibody responses have now been observed in 9 of 9 evaluable patients, up from 8 of 9 in March, with titres maintained at later follow-up.

Dagens aktienyheder 05/05-2026: ISS, ALK-Abelló, Trifork, Rovsing og Expres2ion